Angel Biotech delivers another blow as it calls in administrators

Angel Biotechnology, which makes stem cells for medical research, delivered another blow to investors on Friday, calling for trading of shares to be suspended and sending the share price down over nine per cent.

Angel Biotechnology, which makes stem cells for medical research, delivered another blow to investors on Friday, calling for trading of shares to be suspended and sending the share price down over nine per cent.

The company, which in January announced that it was in discussions with a consortium of overseas organisations with the aim of establishing a strategic relationship between both parties in order to more effectively develop its contract manufacturing business, said Friday that these discussions have ended.

As a result the company has requested the immediate suspension of trading of its shares on AIM, pending clarification of its financial position.

"In view of its trading difficulties, the company intends to appoint administrators and a further announcement will be made as appropriate," was the comment made by the firm.

At the end of January the group said that the future of the group was dependent on it delivering both the proposed joint venture with MMH, but also on it entering a strategic relationship with another party.

It also acknowledged that it would be "extremely difficult" to raise funds through the market at the present time.

Angel, which makes stem cells for medical research, posted wider half year losses at £2.86m for the six month period ended September 30th 2012, most of which is attributable to a write back of accrued revenue and contract liabilities related to joint ventures. The company posted a loss of £241,000 the year before. Revenue for the period slipped to £1.07m from £1.4m previously.

Recommended

Three top-notch Asian stocks to buy
Share tips

Three top-notch Asian stocks to buy

Professional investors Adrian Lim and Pruksa Iamthongthong, managers of the Asia Dragon Trust, pick three of their favourite Asian stocks to buy now.
23 Sep 2022
Why you should short this satellite broadband company
Trading

Why you should short this satellite broadband company

With an ill-considered business plan, satellite broadband company AST SpaceMobile is doomed to failure, says Matthew Partridge. Here's how to short th…
23 Sep 2022
Share tips of the week – 23 September
Share tips

Share tips of the week – 23 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
23 Sep 2022
Momentum investing – and why price matters more than anything else
Investment strategy

Momentum investing – and why price matters more than anything else

The recent fashion for momentum investing, with investors piling into expensive growth stocks, is nothing new, says Merryn Somerset Webb. And the dang…
21 Sep 2022

Most Popular

Earn 4.1% from the best savings accounts
Savings

Earn 4.1% from the best savings accounts

With inflation topping 10%, your savings won't keep pace with the rising cost of living. But you can at least slow the rate at which your money is los…
27 Sep 2022
How much is King Charles III worth?
UK Economy

How much is King Charles III worth?

What will King Charles III inherit from the late Queen? Will he have to pay inheritance tax? And how large is his personal fortune and estate?
23 Sep 2022
Beating inflation takes more luck than skill – but are we about to get lucky?
Inflation

Beating inflation takes more luck than skill – but are we about to get lucky?

The US Federal Reserve managed to beat inflation in the 1980s. But much of that was down to pure luck. Thankfully, says Merryn Somerset Webb, the Bank…
26 Sep 2022